Site-Specific Fluorescent Labeling of Antibodies and Diabodies Using SpyTag/SpyCatcher System for In Vivo Optical Imaging

0301 basic medicine 0303 health sciences Cell Transplantation Acute Lung Injury Graft Survival Green Fluorescent Proteins Optical Imaging Antibodies, Monoclonal Fluorescent Antibody Technique 3. Good health Ligases 03 medical and health sciences Hepatocyte Nuclear Factor 4 Cell Tracking Organ Specificity Antibodies, Bispecific Luminescent Measurements Animals Heterografts Humans Female Luciferases Cells, Cultured Fluorescent Dyes
DOI: 10.1007/s11307-018-1222-y Publication Date: 2018-06-12T11:57:51Z
ABSTRACT
Construction of antibody-based, molecular-targeted optical imaging probes requires the labeling an antibody with a fluorophore. The most common method for doing this involves non-specifically conjugating fluorophore to antibody, resulting in poorly defined, heterogeneous that often have suboptimal vivo behavior. We tested new strategy site-specific label antibody-based using SpyCatcher/SpyTag protein ligase system.We used system site specifically nimotuzumab, anti-EGFR and anti-HER3 diabody. To prevent from interfering antigen binding, we introduced SpyTag SpyCatcher at C-terminus diabody, respectively. Expression binding properties C-terminal antibody-SpyTag diabody-SpyCatcher fusions were similar indicating well tolerated position. Site-specific diabody was performed two steps. First, labeled IRDye800CW-Maleimide IRDye800CW-NHS. Second, conjugated IRDye800CW-SpyCatcher IRDye800CW-SpyTag or confirmed affinity specificity IRDye800CW-labeled biolayer interferometry flow cytometry. analyzed biodistribution tumor accumulation nimotuzumab nude mice bearing xenografts express EGFR HER3, respectively.Expression Site-specifically bound their immobilized targets, cells expressing these selectively accumulated xenografts.These results highlight ease utility modular SpyTag/SpyCatcher fluorescent protein-based probes. Imaging manner will be useful applications such as image-guided surgery broad application other modalities.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (43)
CITATIONS (30)